Literature DB >> 8354019

Effect of continuous arteriovenous haemofiltration on pharmacokinetics of amrinone.

S Lawless1, I Restaino, S Azin, D Corddry.   

Abstract

This case report details the pharmacokinetic adjustments of an amrinone infusion in a paediatric patient who developed multiorgan system failure with anuric renal failure and was prescribed continuous arteriovenous haemofiltration. A significant proportion of clearance of amrinone is nonrenal. Near normal amrinone clearance can occur in patients with hepatic and renal dysfunction if continuous arteriovenous haemofiltration is used. Hepatic dysfunction with renal failure may require a reduction in the continuous amrinone infusion rate as previously reported for neonates.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8354019     DOI: 10.2165/00003088-199325010-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  7 in total

1.  Simplified assay of amrinone in plasma by high-performance liquid chromatography.

Authors:  S Lawless; G Burckart; G Piccola; W Diven; M Miles; A Zaritsky
Journal:  Ther Drug Monit       Date:  1990-11       Impact factor: 3.681

2.  The acute pharmacokinetics and pharmacodynamics of amrinone in pediatric patients.

Authors:  S T Lawless; A Zaritsky; M Miles
Journal:  J Clin Pharmacol       Date:  1991-09       Impact factor: 3.126

Review 3.  Drug dosing during continuous arteriovenous hemofiltration.

Authors:  S K Bickley
Journal:  Clin Pharm       Date:  1988-03

4.  Amrinone metabolism.

Authors:  M P Kullberg; G B Freeman; C Biddlecome; A A Alousi; J Edelson
Journal:  Clin Pharmacol Ther       Date:  1981-03       Impact factor: 6.875

5.  Amrinone in neonates and infants after cardiac surgery.

Authors:  S Lawless; G Burckart; W Diven; A Thompson; R Siewers
Journal:  Crit Care Med       Date:  1989-08       Impact factor: 7.598

6.  Continuous arteriovenous hemofiltration in the critically ill patient. Clinical use and operational characteristics.

Authors:  A Lauer; A Saccaggi; C Ronco; M Belledonne; S Glabman; J P Bosch
Journal:  Ann Intern Med       Date:  1983-10       Impact factor: 25.391

Review 7.  Amrinone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  A Ward; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-12       Impact factor: 9.546

  7 in total
  2 in total

1.  Elimination of amrinone during continuous veno-venous haemofiltration after cardiac surgery.

Authors:  A Hellinger; K Wolter; G Marggraf; R Pentz; E Fritschka
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.